Target intelligence / Profile preview

Voltage-gated calcium channel protein complex (VGCC)

Target
VGCC
Molecular classification
Ion channel, Voltage-gated ion channel, Transmembrane protein complex, Multi-subunit protein complex
01

Overview

The **Calcium channel protein complex** is a pentameric or tetrameric assembly comprising a central pore-forming alpha-1 subunit and auxiliary beta, alpha-2-delta, and gamma subunits[1][3][7]. This architecture forms highly regulated transmembrane ion channels controlling calcium influx in response to cellular signals and membrane depolarization, thereby influencing diverse processes such as muscle contraction, neurotransmitter release, hormone secretion, and gene transcription[1][3][6][7]. Calcium channels exist as various subclasses (L-type, N-type, P/Q-type, R-type, T-type) with distinct tissue distribution and pharmacology, and their dysfunction or altered expression is implicated in multiple disease states ranging from cardiac arrhythmias to cancer and neurological disorders[2][6]. Drug targeting often involves channel blockers that modulate their conductance or trafficking[4][6][2].

Other names
Calcium channel complexVoltage-gated calcium channel complexL-type calcium channel complexCav complex
02

Mechanism of action

Inhibition of Ca\(^{2+}\) influx by blocking the pore-forming subunit Modulation of channel gating or trafficking by targeting auxiliary subunits Alteration of cell signaling and contraction

03

Biological functions

Signal transductionRegulation of muscle contractionNeurotransmitter release (synaptic transmission)Gene transcription modulationHormone secretionCell proliferation and differentiation
04

Disease associations

Cardiovascular disease (e.g., arrhythmia, hypertension)Neurodegenerative disease (e.g., epilepsy)Cancer (e.g., roles in head and neck, melanoma)InflammationOther (e.g., diabetes, pain disorders)
05

Safety considerations

Cardiac conduction disorders (e.g., heart block, bradycardia)HypotensionNeurological side effects (e.g., dizziness, headache)Possible off-target effects on nonchannel complexes
06

Interacting drugs

Calcium channel blockers (e.g., nifedipine, verapamil, amlodipine, diltiazem)

2 more in the full profile.

07

Biomarkers

Upregulation of specific channel subunits (e.g., CACNA2D1, Cav3.1, TRPM7, TRPV1 in cancer)Calcium flux or channel activity measurements

Beyond the preview

Go deeper on Voltage-gated calcium channel protein complex (VGCC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voltage-gated calcium channel protein complex (VGCC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call